Granulomatosis with Polyangiitis (GPA) – Overview
Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease causing inflammation of blood vessels and granuloma formation in organs such as the nose, lungs, and kidneys.
Things worth knowing about "Granulomatosis with Polyangiitis"
Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease causing inflammation of blood vessels and granuloma formation in organs such as the nose, lungs, and kidneys.
What is Granulomatosis with Polyangiitis?
Granulomatosis with polyangiitis (GPA) – formerly known as Wegener granulomatosis – is a rare, chronic, inflammatory autoimmune disease. It belongs to the group of ANCA-associated vasculitides, meaning the immune system attacks the body's own blood vessels. The disease is characterized by the formation of inflammatory nodules called granulomas and inflammation of small to medium-sized blood vessels (vasculitis). It primarily affects the upper and lower airways and the kidneys, but can involve nearly any organ in the body.
Causes
The exact cause of GPA is not yet fully understood. It is an autoimmune disease in which the immune system becomes dysregulated and attacks the body's own tissues. The following factors are under discussion:
- Genetic predisposition: Certain genetic characteristics are associated with increased risk.
- Infections: Bacterial infections, particularly with Staphylococcus aureus, are considered possible triggers.
- Immune dysfunction: GPA is frequently associated with ANCA antibodies (anti-neutrophil cytoplasmic antibodies), especially c-ANCA directed against proteinase 3 (PR3), which trigger inflammatory reactions in vessel walls.
- Environmental factors: Exposure to certain chemicals or dust particles has been considered as a possible risk factor.
Symptoms
The symptoms of GPA are diverse and depend on which organs are affected. Common manifestations include:
Upper Airways
- Chronic nasal congestion or nosebleeds
- Sinus pain and pressure (sinusitis)
- Hoarseness or difficulty swallowing due to laryngeal involvement
- In advanced stages: destruction of the nasal septum resulting in a saddle nose deformity
Lungs (Lower Airways)
- Cough, sometimes with bloody sputum (hemoptysis)
- Shortness of breath and dyspnea
- Pulmonary infiltrates or nodules visible on imaging
Kidneys
- Blood in the urine (hematuria)
- Protein in the urine (proteinuria)
- Reduced kidney function, potentially progressing to kidney failure
General Symptoms
- Fatigue and general malaise
- Fever and night sweats
- Unintentional weight loss
- Joint and muscle pain
Other Possible Organ Manifestations
- Eyes: redness, pain, visual disturbances (episcleritis, uveitis)
- Skin: skin hemorrhages (purpura), ulcerations
- Nervous system: numbness, weakness (peripheral neuropathy)
Diagnosis
Diagnosing GPA requires a combination of clinical examination, laboratory testing, and tissue sampling:
- Blood tests: Detection of c-ANCA/PR3-ANCA antibodies (positive in approximately 80–90% of patients with active GPA), inflammatory markers such as CRP and ESR, complete blood count, and kidney function tests
- Urinalysis: Detection of blood or protein in the urine as indicators of kidney involvement
- Imaging: Chest X-rays and CT scans of the lungs and sinuses to identify granulomas and areas of inflammation
- Biopsy: Tissue sampling (e.g., from the nasal mucosa, lung, or kidney) for direct confirmation of granulomas and vasculitis
- Kidney biopsy: Used when renal involvement is suspected to assess the extent of damage
Diagnosis is also guided by the classification criteria of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).
Treatment
GPA is a serious condition that can be life-threatening without treatment. The goals of therapy are to induce remission (reduce disease activity) and to maintain it long-term.
Remission Induction
- Rituximab: A monoclonal antibody that depletes B cells of the immune system. It is now considered a standard therapy, especially for severe disease.
- Cyclophosphamide: An immunosuppressant used primarily in life-threatening manifestations.
- Glucocorticoids (corticosteroids): Used at high doses in combination to rapidly suppress inflammation.
Remission Maintenance
- Rituximab (every 6 months) or azathioprine and methotrexate to prevent relapses
- Glucocorticoids are gradually tapered over time.
Additional Measures
- Regular monitoring of kidney function, blood pressure, and ANCA levels
- Infection prophylaxis (e.g., against Pneumocystis jirovecii) during immunosuppressive therapy
- Nephrology co-management or dialysis if kidney function is significantly impaired
Prognosis
With modern immunosuppressive therapy, the prognosis of GPA has improved significantly. Many patients achieve long-term remission. However, relapses are common, making regular medical follow-up essential. Without treatment, the disease was historically fatal within months. Early diagnosis and consistent therapy are therefore critical to improving outcomes.
References
- Jennette JC et al. - 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
- Yates M et al. - EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594.
- Falk RJ, Gross WL - Granulomatosis with Polyangiitis (Wegener's). UpToDate, Wolters Kluwer. 2023.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryCalorie deficit
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Granulomatosis with Polyangiitis-en